Precise diagnosis is key to choosing the optimal chemotherapy for large B-cell lymphoma. In this test-specific episode of the "Answers From the Lab" podcast, Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test accurately distinguishes among multiple subtypes of this cancer.

"PM3CX is a qualitative RNA test," Dr. Rimsza says. "It first tells you if the patient has primary mediastinal large B-cell lymphoma or diffuse large B-cell lymphoma (DLBCL). The test can also identify subtypes of DLBCL."

Using gene expression profiling, the test avoids challenges associated with immunostaining and biopsies of delicate tissue. "The molecular test is very accurate and reproducible," Dr. Rimsza says. "There is no other molecular test like this, for this disease."

Test results can directly impact treatment decisions. "Clinicians need to know whether a patient has the more typical DLBCL — which gets one type of chemotherapy — or in fact has the primary mediastinal large B-cell type, which gets a different chemotherapy," Dr. Rimsza says.

Listen to learn more about Mayo Clinic Laboratories' PM3CX test.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PM3CX   | Lymph3CX Assay, Primary Mediastinal Large B-cell Lymphoma and Diffuse Large B-cell Lymphoma, mRNA Gene Expression, NanoString, Tissue

Useful information

Only indicated for formalin-fixed paraffin-embedded specimens from patients diagnosed with large B-cell lymphoma.

Specimen requirements

Submit only 1 of the following specimens:

Preferred

• Specimen Type: Tissue slides
• Slides: 1 stained and 7 unstained
• Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 7 consecutive, unstained, 5-micron thick sections placed on positively charged slides.
• Additional Information: Paraffin embedded specimens can be from any anatomic location (skin, soft tissue, lymph node, etc).

Acceptable

• Specimen Type: Tissue block
• Collection Instructions: Submit a formalin-fixed, paraffin-embedded tumor tissue block.

Specimen minimum volume

• Minimum 60% tumor with or without macrodissection.
• Minimum required unstained tissue section input: 0.12 mm(3)

Performance information

• Analytic time: 7 to 12 days
• Day(s) and time(s) performed: Monday through Friday

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less